Eli Lilly has discontinued two of three mid-stage clinical trials of its oral GLP-1 diabetes drug candidate naperiglipron citing strategic business reasons. The remaining phase 2 trial targets obesity and overweight patients and is expected to complete by 2026, informing future development steps. This shift comes as Lilly prepares regulatory and market moves for its leading oral GLP-1, orforglipron, amid competitive pressure and evolving obesity therapy landscapes.